Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720®: Immunogenicity and safely in rhesus macaques

Human Vaccines

Volumn 2, Issue 5, 2006, Pages 222-226

  Langermans, Jan A M ^a   Hensmann, Meike ^a   Van Gijlswijk, Marcel ^a   Zhang, Dongmei ^b   Pan, Weiqing ^b   Giersing, Birgitte K ^c   Locke, Emily ^c   Dubovsky, Filip ^c   Wittes, Janet ^d   Thomas, Alan W ^a,e  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c PATH Malaria Vaccine Initiative   (United States)

^d University of Iowa   (United States)

^e Department of Parasitology ^*  (Netherlands)

Author keywords

Abscess; Immunogenicity; Malaria vaccine; Montanide ISA 720; PfCP2.9 chimera; Rhesus

Indexed keywords

ALANINE AMINOTRANSFERASE; APICAL MEMBRANE PROTEIN 1; ASPARTATE AMINOTRANSFERASE; CHIMERIC PROTEIN; CREATININE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MONTANIDE ISA 720; PARASITE ANTIGEN; PROTEIN PFCP2.9; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ABSCESS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; IMMUNE RESPONSE; IMMUNOGENICITY; INTERFERON PRODUCTION; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN DOMAIN; VACCINATION;

EID: 33751207115     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.2.5.3276     Document Type: Article

References (26)

1. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunology 1999; 21:133-2.
2. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 2001; 69:3286.
3. Kumar S, Collins W, Egan A, Yadava A, Garraud O, Blackman MJ, Guevara Patino JA, Diggs C, Kaslow DC. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun 2000; 68:2215-23.
4. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 2002; 70:6961-7.
5. Narum DL, Ogun SA, Thomas AW, Holder AA. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun 2000; 68:2899-906.
6. Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, Pollock B, Pye D. Immunisation with recombinant AMA1 protects mice against infection with Plasmodium chabaudi. Vaccine 1998; 16:240-7.
7. Hirunpetcharat C, Tian JH, Kaslow DC, van Rooijen N, Kumar S, Berzofsky JA, Miller LH, Good MF. Complete prorective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titre, but not with effector CD4+ T cells. J Immunol 1997; 159:3400-11.
8. Ling IT, Ogun SA, Momin P, Richards RL, Garcon N, Cohen J, Ballou WR, Holder AA. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine 1997; 15:1562-7.
9. Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, Irving DO, Briggs WR, Mai A, Ginny M, Adiguma T, Rare L, Giddy A, Reber-Liske R, Stuerchler D, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000; 18:2504-11.
10. Rogers WO, Baird JK, Kumar A, Tine JA, Weiss W, Aguiar JC, Gowda K, Gwadz R, Kumar S, Gold M, Hoffman SL. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun 2001; 69:5565-72.
11. Burns JM, Jr., Flaherty PR, Romero MM, Weidanz WP. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1. Vaccine 2003; 21:1843-52.
12. Pan W, Huang D, Zhang Q, Qu L, Zhang D, Zhang X, Xue X, Qian F. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. J Immunol 2004; 172:6167-74.
13. Mueller MS, Renard A, Boato F, Vogel D, Naegeli M, Zurbriggen R, Robinson JA, Pluschke G. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect Immun 2003; 71:4749-58.
14. Nair M, Hinds MG, Coley AM, Hodder AN, Foley M, Anders RF, Norton SR. Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1). J Mol Biol 2002; 322:741.
15. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA, Angov E, Ling IT, Fegeding K, Morgan WD, Ockenhouse C, Birdsall B, Feeney J, Lyon JA, Holder AA. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. JMB 2001; 307:1381.
16. Hodder AN, Crewther PE, Matthew ML, Reid GE, Moritz RL, Simpson RJ. The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem 1996; 271:29446-52.
17. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun 2005; 73:287-97.
18. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, Dubovsky F, Tierney E, Gleiter CH, Boehmer G, Luty AJ, Ramharter M, Thornton GB, Kremsner PG, Nardin EH. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 2005; 73:3587-97.
19. Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003; 22:30-41.
20. Lawrence GW, Saul A, Giddy AJ, Kemp R, Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 1997; 2:176-8.
21. Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A, Blackman MJ, Thomas AW. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun 2002; 70:4471-6.
22. Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, Percell S, Izu AE, Hirabayashi S, Burke RL, Duliege AM. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999; 180:1700-3.
23. Belshe RB, Newman FK, Frey SE, Couch RB, Treanor JJ, Tacket CO, Yan L. Dose-dependent neutralizing-antibody responses to vaccinia. J Infect Dis 2004; 189:493-7.
24. Palache AM, Beyer WE, Luchters G, Volker R, Sprenger MJ, Masurel N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine 1993; 11:892-908.
25. Toledo H, Baly A, Castro O, Resik S, Laferte J, Rolo F, Navea L, Lobaina L, Cruz O, Miguez J, Serrano T, Sierra B, Perez L, Ricardo ME, Dubed M, Lubian AL, Blanco M, Millan JC, Ortega A, Iglesias E, Penton E, Martin Z, Perez J, Diaz M, Duarte CA. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 Infected human volunteers. Vaccine 2001; 19:4328-36.
26. Langermans JAM, Schmidt A, Vervenne RAW, Birkett AJ, Calvo-Calle JM, Hensmann M, Thornton GB, Dubovsky F, Weiler H, Nardin E, Thomas AW. Effect of adjuvant on reacrogenicity and long-term immunogenicity of the malaria vaccine ICC-1132 in macaques. Vaccine 2005; 23:4935-43.